CEO Christoffer Ekström Featured on BioBiz Buzz Podcast

AI-based software solutions are increasingly being used as a second pair of eyes to help clinicians with the early diagnosis of diseases. With skin cancer seeing increasing rates of incidence and mortality, software solutions hold the key to helping clinicians with timely diagnosis.

In this episode of BioBiz Buzz, your host Shani Alexander sits down with Christoffer Ekström, CEO of AI Medical Technology, a Swedish-based company which has developed the Dermalyser, a diagnostic decision support system to help healthcare professionals classify skin cancer, such as malignant melanoma, using image analysis combined with the company's algorithm. All that is needed is a smartphone with the Dermalyser app, a compatible dermatoscope, and a clinical environment with trained healthcare staff.

Listen to the Full Episode

A Fundamental Shift in Diagnosis

Ekström explains that the company's innovation is more than a technological breakthrough; it represents a fundamental shift in how skin cancer is diagnosed. For patients, it means faster diagnosis, fewer unnecessary surgeries, and potentially life-saving decisions made sooner.

This episode provides insights into a solution that offers hope and will bring peace of mind to the millions of people with a suspected skin lesion.